Loading data for ABCL — first visit, this takes a few seconds.

Alert

AbCellera Biologics Inc. (ABCL)

NasdaqGS: ABCL · Real-Time Price · USD

12.50

+1.89 (17.81%)

At close: Aug 24, 2026, 8:00 PM

The price, the headline numbers and the latest news, in one place.

17.81% (1D)

No data available

Bid	8.88
Market Cap	3.44B
Revenue (ttm)	66.17M
Net Income (ttm)	-164.66M
	1.19
	-0.51
	n/a
	-14.84
P/B (ttm)	3.63
P/S (ttm)	51.96
Earnings Date	Nov 5, 2026

Ask	15.24
Volume	10,613,968
Avg. Volume (20D)	7,998,014
Open	11.00
Previous Close	10.61
Day's Range	10.99 - 12.50
52-Week Range	2.75 - 12.50
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ABCL

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, su...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 11, 2020

Employees 562

Stock Exchange NasdaqGS

Ticker Symbol ABCL

Website https://www.abcellera.com

Full Company Profile

Financial Performance

In 2025, AbCellera Biologics's revenue was 75.13M, an increase of 160.56% compared to the previous year's 28.83M. Earnings were -146.41M, a decrease of -10.1%.

Financial Statements

Earnings Surprise

AbCellera Biologics has released their quarterly earnings on Aug 5, 2026:

Revenue of $4.05M misses estimates by $0, with -76.29% YoY decline.
EPS of -0.18 misses estimates by -0.02, with -50.00% YoY decline.

Next Earnings Release

AbCellera Biologics Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

1 week ago · Insider Monkey

AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity

AbCellera Biologics (NASDAQ:ABCL) has seen its stock price jump by 64 percent week-on-week, making it the top-performing mid-cap stock in the US market last week, thanks to strong clinical trial resul...

1 week ago · Insider Monkey

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cel...

1 week ago · MT Newswires

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Producer Inflation Data Release

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra

1 week ago · Motley Fool

AbCellera (ABCL) Q2 2026 Earnings Call Transcript

Lead program ABCL635 Phase 2 enrollment complete with data expected in August.

2 weeks ago · Simply Wall St.

AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?

AbCellera Biologics recently reported that its investigational antibody ABCL635 achieved statistically significant Phase 2 results, with a single 600 mg subcutaneous dose reducing both the frequency a...

Page 1 of 2

AbCellera Biologics Inc. (ABCL)